klaus romero - which diseases have benefited from the development of quantitative solutions?
Published 4 years ago • 255 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
2:16
klaus romero - what does c-path do?
-
1:52
klaus romero - who can access the quantitative solutions that c-path has developed?
-
30:30
ep. 41 - critical path institute's klaus romero
-
0:48
klaus romero - what does c-path's quantitative medicine group do?
-
4:18
c-path's impact on rare disease drug development - klaus romero, ceo
-
9:00
question #16 - any successful alternate treatments?
-
5:09
how are pharmaceutical companies using artificial intelligence?
-
24:22
2022 rdca-dap workshop: case study 3, duchenne regulatory science consortia (d-rsc)
-
1:13
klaus romero - what makes c-path unique in the regulatory science environment?
-
16:22
klaus romero, a chief science officer, gets the star treatment
-
3:32
klaus romero - what are clinical trial simulators; how do they reduce the costs of clinical trials?
-
26:24
the critical path institute: 15 years of impact
-
1:44
c path rare and orphan conference closing remarks klaus romero
-
4:12
why are high-quality standardized databases so critical for drug development?
-
48:02
rdca-dap - value of integrated data and analytics in rare disease drug development
-
2:14
martha brumfield - what is c-path's purpose and history?
-
0:40
the kidneys
-
37:16
medical ai: promises and challenges by leo kärkkäinen